1. Home
  2. NXDT vs KROS Comparison

NXDT vs KROS Comparison

Compare NXDT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NXDT

NexPoint Diversified Real Estate Trust

HOLD

Current Price

$4.99

Market Cap

259.1M

Sector

Finance

ML Signal

HOLD

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

HOLD

Current Price

$10.22

Market Cap

222.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXDT
KROS
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.1M
222.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NXDT
KROS
Price
$4.99
$10.22
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$21.86
AVG Volume (30 Days)
145.9K
277.4K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
9.66%
N/A
EPS Growth
N/A
146.00
EPS
0.99
N/A
Revenue
N/A
$243,864,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2,751.79
P/E Ratio
$5.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.55
$9.69
52 Week High
$5.61
$22.55

Technical Indicators

Market Signals
Indicator
NXDT
KROS
Relative Strength Index (RSI) 46.14 40.90
Support Level $4.48 $9.79
Resistance Level $5.55 $12.43
Average True Range (ATR) 0.26 0.46
MACD -0.03 -0.06
Stochastic Oscillator 19.87 26.80

Price Performance

Historical Comparison
NXDT
KROS

About NXDT NexPoint Diversified Real Estate Trust

NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: